Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research
American Journal of Epidemiology · 04.11.2024 · 193 (11) · 1625-1631
DOI: 10.1093/aje/kwae087 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, online erschienen am 23.05.2023. Verfasst von Shirley V Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA 02120, United States. Hauptthemen laut MEDLINE: Pharmacoepidemiology. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Real-world evidence (RWE) studies are increasingly used to inform policy and clinical decisions. However, there remain concerns about the credibility and reproducibility of RWE studies. While there is universal agreement on the critical importance of transparent and reproducible science, the building blocks of open science practice that are common across many disciplines have not yet been built into routine workflows for pharmacoepidemiology and outcomes researchers. Observational researchers should highlight the level of transparency of their studies by providing a succinct statement addressing study transparency with the publication of every paper, poster, or presentation that reports on an RWE study. In this paper, we propose a framework for an explicit transparency statement that declares the level of transparency a given RWE study has achieved across 5 key domains: (1) protocol, (2) preregistration, (3) data, (4) code-sharing, and (5) reporting checklists. The transparency statement outlined in the present paper can be used by research teams to proudly display the open science practices that were used to generate evidence designed to inform public health policy and practice. While transparency does not guarantee validity, such a statement signals confidence from the research team in the scientific choices that were made.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA 02120, United States.
- Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, Faculty of Health Sciences, University of Southern Denmark, 5230 Odense M, Denmark.
ORCID-Profile: Shirley V Wang, Anton Pottegård
Zitieren
APA
Wang, S. V., & Pottegård, A. (2024). Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research. American Journal of Epidemiology, 193(11), 1625-1631. https://doi.org/10.1093/aje/kwae087
Vancouver
Wang SV, Pottegård A. Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research. American Journal of Epidemiology. 2024;193(11):1625-1631. doi:10.1093/aje/kwae087
BibTeX
@article{Wang2024,
author = {Wang, Shirley V and Pottegård, Anton},
title = {Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research},
journal = {American Journal of Epidemiology},
year = {2024},
volume = {193},
number = {11},
pages = {1625--1631},
doi = {10.1093/aje/kwae087}
}
EUVIMED